All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Ongoing | 2004-000411-25 | A phase II trial and "scheduling finding" of cetuximab in combination with rapidly alternating chemo-radiation in unresectable,locally advanced, squamous cell carcinoma of the head and neck (HNC) | not-yet-due | |
| Ongoing | 2004-002376-42 | PHASE II TRIAL OF SEQUENTIAL CHEMO-IMMUNOTHERAPY WITH CAPECITABINE PLUS INTERFERON ALPHA2a FOLLOWED BY IL-2 IN PATIENTS WITH METASTATIC KIDNEY CANCER | not-yet-due | |
| Ongoing | 2005-005846-37 | STUDY MULTICENTRIC PILOT OF CHEMOTHERAPY WITH CAPECITABINE, OXALIPLATIN LOHP IRINOTECAN Cpt-11 IN PATIENTS WITH Colorectal METASTATIC cancer | not-yet-due | |
| Ongoing | 2006-001007-11 | OPEN-LABEL, MULTICENTER, PHASE II STUDY OF FIRST- LINE BI-WEEKLY IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV (FOLFOXIRI) IN COMBINATION WITH BEVACIZUMAB IN PATIENTS WITH METASTATIC COLORECTAL CANCER... | not-yet-due | |
| Ongoing | 2006-004478-29 | DOCETAXEL AND PREDNISON IN ASSOCIATION WITH METRONOMIC THERAPY WITH CICLOPHOSPHAMIDE AND CELECOXIN IN HORMONE-REFRACTORY PROSTATIC CANCER PATIENTS : PHASE II CLINICAL TRIAL WITH PHARMACODYNAMIC AND PH... | not-yet-due | |
| Ongoing | 2007-002886-11 | AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE III STUDY OF SECOND-LINE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER PATIENTS WHO HAVE RECEIVED FIRST-LINE CHEMOTHERAPY PLUS B... | not-yet-due | |
| Ongoing | 2007-002909-49 | Neoadjuvant chemotherapy in patients affected by prostatic cancer locally advanced (non metastatic. Phase II study | not-yet-due | |
| Completed, but no date | 2008-001537-10 | A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER | bad-data | |
| Ongoing | 2008-001763-11 | LOW-DOSE METRONOMIC TEMOZOLOMIDE AND SORAFENIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME: A PHASE II CLINICAL TRIAL WITH EVALUATION OF CLINICAL, BIOLOGIC AND PHARMACODYNAMIC EFFECTS OF THE C... | not-yet-due | |
| Ongoing | 2008-003160-19 | CETUXIMAB PLUS IRINOTECAN IN PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER PATIENTS SELECTED ON THE BASIS OF KRAS MUTATION AND EGFR INTRON 1 CA TANDEM REPEATS: PHASE II PROSPECTIVE STUDY AND RETROSP... | not-yet-due | |
| Ongoing | 2009-013402-14 | INduction chemoThERapy followed by CEtuximab Plus definiTive radiOtheRapy versus radiation plus cisplatin | not-yet-due | |
| Completed, but no date | 2009-014556-29 | PHASE II TRIAL OF FOLFOXIRI PLUS PANITUMUMAB AS FIRST-LINE TREATMENT FOR KRAS AND BRAF WILD-TYPE METASTATIC COLORECTAL CANCER | bad-data | |
| Ongoing | 2009-017596-26 | Terapia di II linea con Docetaxel + Lanreotide in pazienti con carcinoma prostatico metastatico ormonorefrattario e in progressione in corso di chemioterapia di I linea con Docetaxel. Studio di fase I... | not-yet-due | |
| Ongoing | 2011-000840-70 | INDUCTION CHEMOTHERAPY WITH FOLFOXIRI PLUS CETUXIMAB AND MAINTENANCE WITH CETUXIMAB OR BEVACIZUMAB THERAPY IN UNRESECTABLE KRAS WILD-TYPE METASTATIC COLORECTAL CANCER PATIENTS STUDIO DI FASE II RAN... | not-yet-due | |
| Ongoing | 2014-001126-15 | A phase II single-arm study of cetuximab plus irinotecan as rechallenge 3rd-line treatment of kras, nras and braf wild-type irinotecan-pretreated metastatic colorectal cancer patients progressing aft... | not-yet-due | |
| Ongoing | 2014-004436-19 | First-line FOLFOXIRI plus bevacizumab followed by reintroduction of FOLFOXIRI plus bevacizumab at progression versus FOLFOX plus bevacizumab followed by FOLFIRI plus bevacizumab at progression in firs... | not-yet-due | |
| Ongoing | 2015-003888-10 | The PANDA STUDY: RANDOMIZED PHASE II STUDY OF FIRST-LINE FOLFOX PLUS PANITUMUMAB versus 5FU PLUS PANITUMUMAB IN RAS AND BRAF WILD-TYPE METASTATIC COLORECTAL CANCER ELDERLY PATIENTS Studio PANDA: St... | not-yet-due | |
| Ongoing | 2016-004394-40 | Randomized phase III study of triplet mFOLFOXIRI plus PANITUMUMAB versus mFOLFOX6 plus PANITUMUMAB as initial therapy for unresectable RAS and BRAF wild-type metastatic colorectal cancer patients S... | not-yet-due | |
| Exempt | 2017-000353-39 | The CONFRONT Phase I – II Trial: ACtivatiON oF immune RespONse in paTients with R-M Head and Neck Cancer. Multimodality immunotherapy with Avelumab, short course radiotherapy and Cyclophosphamide in H... | 2022-05-25 | not-yet-due |
| Ongoing | 2017-000562-30 | A Single-Arm, Open-Label, Multicenter, Phase IIIb Clinical Trial with NIVolumab in Subjects with Recurrent or Metastatic Platinum-refrACTORy Squamous Cell Carcinoma of the Head and Neck (SCCHN) Stu... | not-yet-due | |
| Ongoing | 2017-000977-35 | Randomized phase II study of FOLFOXIRI plus BEVACIZUMAB plus ATEZOLIZUMAB versus FOLFOXIRI plus BEVACIZUMAB as first-line treatment of unresectable metastatic colorectal cancer patients studio di f... | not-yet-due | |
| Ongoing | 2017-003582-10 | PHASE II STUDY OF PREOPERATIVE CHEMORADIOTHERAPY PLUS AVELUMAB IN PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER STUDIO DI FASE II DI CHEMIORADIOTERAPIA PREOPERATORIA IN ASSOCIAZIONE AD AVELUMAB IN P... | not-yet-due | |
| Not reported | 2017-005017-31 | DENOSUMAB IN EBV RELATED NASOPHARYNGEAL CARCINOMA (NPC) AS A MODEL FOR RANK-MEDIATED IMMUNOLOGIC MODULATION OF VIRUS-RELATED TUMOURS – DERN STUDY DENOSUMAB NEL CARCINOMA NASOFARINGEO (NPC) ASSOCIAT... | 2023-06-05 | due-trials |
| Ongoing | 2018-000737-12 | The CARACAS Study. Randomized phase 2 trial of cetuximab and avelumab or avelumab alone for unresectable, locally advanced or metastatic squamous cell anal carcinoma (SCCAC) progressed after at least ... | not-yet-due | |
| Ongoing | 2018-003669-32 | GRANISETRON TRANSDERMAL SYSTEM (GTDS) IN PREVENTING NAUSEA AND VOMITING INDUCED BY CISPLATIN-BASED CHEMOTHERAPY AND CONCURRENT RADIOTHERAPY FOR HEAD AND NECK CANCER GRANISTERON CEROTTO TRANSDERMICO... | not-yet-due | |
| Ongoing | 2019-001501-24 | PHASE II STUDY OF AVELUMAB AND CETUXIMAB AND MODIFIED FOLFOXIRI AS INITIAL THERAPY FOR RAS WILD-TYPE UNRESECTABLE METASTATIC COLORECTAL CANCER PATIENTS Studio di fase II di FOLFOXIRI modificato, CE... | not-yet-due | |
| Other | 2019-002834-35 | Randomized phase II study of PAnitumumab REchallenge followed by REgorafenib versus the reverse sequence in RAS and BRAF WILD-TYPE chemorefractory metastatic colorectal cancer patients. STUDIO RAND... | not-yet-due | |
| Ongoing | 2019-004875-38 | The induction and maintenance treatment with PARP inhibitor and immunotherapy in HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC) Trattamento di induzione e mantenimento con inibitore di ... | not-yet-due | |
| Exempt | 2020-000923-37 | A phase 1/2 study exploring the safety and activity of Trifluridine/tipiracil in combination with capecitabine and bevacizumab in metastatic colorectal cancer patients. Studio di fase 1/2 su toller... | not-yet-due | |
| Other | 2020-002613-17 | A phase II, open-label study improving compliance and time of treatment after obtaining complete response through a tailored schedule of sonidegib in locally advanced basal cell carcinomas (BCC) – the... | not-yet-due | |
| Ongoing | 2020-003440-92 | TremelImumab aNd durvalumab combination For the non-operatIve management (NOM) of Microsatellite InstabiliTY (MSI)-high resectable gastric or gastroesophageal junction cancer: The multicentre, single-... | not-yet-due | |
| Other | 2020-004649-35 | Pembrolizumab and olaparib in recurrent/metastatic, platinum resistant nasopharyngeal cancer Pembrolizumab e Olaparib nel cancro nasofaringeo recidivante/metastatico, resistente al platino | not-yet-due | |
| Ongoing | 2021-001206-29 | ShorTrip study - Phase II study of Short-course radiotherapy followed by consolidation chemotherapy with the Triplet FOLFOXIRI as total neoadjuvant therapy for locally advanced rectal cancer. ShorT... | not-yet-due | |
| Ongoing | 2021-002169-16 | EXPLOITING CIRCULATING TUMOUR DNA TO INTENSIFY THE POST-OPERATIVE TREATMENT OF STAGE III AND HIGH-RISK STAGE II RESECTED COLON CANCER PATIENTS WITH ADJUVANT FOLFOXIRI AND/OR POST-ADJUVANT TRIFLURIDINE... | not-yet-due | |
| Ongoing | 2022-000601-27 | Window-of-opportunity study of chemo-immunotherapy in patients with resectable Merkel Cell Carcinoma prior to surgery: the MERCURY trial Studio di chemio-immunoterapia preoperatoria in pazienti con... | not-yet-due |